Galderma and L’Oréal Forge New Scientific Partnership

Galderma has announced a significant new partnership with L’Oréal, aimed at advancing dermatology research and development. This collaboration is set to leverage complementary research projects to develop cutting-edge technologies in dermatology, particularly targeting skin ageing.

As part of this partnership, L’Oréal will acquire a 10% stake in Galderma, reflecting its confidence in Galderma's leadership and long-term growth potential in the dermatology sector. This investment underscores the shared commitment of both companies to innovation and growth in the dermatology and beauty markets.

Flemming Ørnskov, CEO of Galderma, welcomed the collaboration, stating, “We are on a journey of growth and innovation in dermatology. L’Oréal’s investment is a testament to our strategy and growth potential. We look forward to exploring new scientific partnership opportunities together.”

L’Oréal has secured the stake from Sunshine SwissCo AG, Abu Dhabi Investment Authority, and Auba Investment Pte. Ltd. Michael Bauer, Partner at EQT, noted, “This transaction supports Galderma’s growth in the dermatology market. Partnering with L’Oréal reflects our commitment to Galderma’s success.”

Galderma has a 40-year history of innovation in dermatology, focusing on injectable aesthetics, dermatological skincare, and therapeutic dermatology. This new partnership with L’Oréal is expected to enhance their R&D capabilities and expand their product portfolios.

A special investor call will be hosted by Galderma at 15:00 CEST today to discuss this announcement further. Interested parties can register on the Galderma Investor Relations website.